← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Tesamorelin × Ipamorelin × 2 of 4 selected View comparison

Tesamorelin

Stabilised GHRH analogue

Remove
VS

Ipamorelin

GH secretagogue

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target TesamorelinIpamorelin
✓ —
— ✓

Pathway Map

This is a schematic, not a claim that every step shown has been directly demonstrated for each compound. The receptor immediately after each compound is its direct, structurally-confirmed target; anything shown beyond that receptor represents the broader documented signalling axis for that receptor family in general, not a compound-specific downstream finding.

Tesamorelin → GHRHR (direct target) → Pituitary → GH → IGF-1 Steps after GHRHR are the general GH-axis cascade, not a compound-specific demonstrated effect.
Ipamorelin → GHSR1a (direct target) → Pituitary/hypothalamic signalling → GH Steps after GHSR1a are the general ghrelin-pathway cascade, not a compound-specific demonstrated effect.

What These Compounds Share

Shared research line

All selected compounds are catalogued under Peak.

Shared pathway tags
GH

Key Differences

Tesamorelin GHRHR is a direct target of Tesamorelin that none of the other selected compounds share. A stabilised GHRH analogue with substantial human clinical characterisation.
Ipamorelin GHSR1a is a direct target of Ipamorelin that none of the other selected compounds share. Acts through GHSR rather than the GHRH receptor.

Compound Detail

Tesamorelin
What is it?
A lab-made version of a hormone that tells your pituitary gland to release growth hormone.
What are people researching/using it for?
Approved and studied for reducing abdominal fat in specific medical contexts.
Other uses being trialed
General growth-hormone axis research
Worth knowing
Approved for a specific indication in branded formulations, backed by two pivotal randomized trials (404 and 412 HIV-positive participants) showing significant visceral-fat reduction versus placebo over 26 weeks; broader research (e.g. cognition, see below) continues in other contexts with less consistently positive results.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Stimulates GHRH receptors on pituitary somatotrophs, promoting endogenous GH secretion and downstream IGF-1 signalling.
Synthetic peptide · Synthetic analogue
Primary Targets & Biological System
GH axis / pituitary signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A stabilised analogue of growth-hormone-releasing hormone (GHRH) that binds the GHRH receptor on somatotroph cells in the pituitary gland, stimulating them to release the body's own growth hormone (GH) in a pulsatile pattern similar to natural GHRH signalling. Released GH then acts on the liver and other tissues to stimulate IGF-1 production, which mediates many of GH's downstream effects. Because this mechanism works through the body's own pituitary GH release rather than delivering synthetic GH directly, its effects depend on a functioning pituitary gland.
Research Areas
GH-axis physiologyVisceral adipose tissueMetabolic/endocrine research
Research Profile
Human administration: Extensive Preclinical: Available
Pharmacokinetics
Short-lived; not displayed as a single universal value without a direct source.
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
A stabilised GHRH analogue with substantial human clinical characterisation.
Considerations
Research Limitations
Approved for a specific indication in branded formulations, backed by two pivotal randomized trials (404 and 412 HIV-positive participants) showing significant visceral-fat reduction versus placebo over 26 weeks; broader research (e.g. cognition, see below) continues in other contexts with less consistently positive results.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Cognitive function in aging/HIV
A randomized, open-label Phase II trial (73 participants, multicenter -- UC San Diego, UCSF, USC) tested tesamorelin for neurocognitive function in adults with HIV and abdominal obesity. The treatment group showed a trend toward improvement, but the difference versus standard-of-care was not statistically significant -- an example of a real trial with a null result, included here for that reason rather than to suggest a benefit was shown.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Tesamorelin · A$149.95 A$169.95
Browse products →
View Research Sources (4) →
EGRIFTA (tesamorelin) Prescribing Information
FDA Prescribing Information — EGRIFTA · Regulatory document Human

Supports: mechanism_summary, primary_targets

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Journal of Acquired Immune Deficiency Syndromes, 2010 · Human Human · 404 HIV-infected patients with excess abdominal fat · Subcutaneous · PMID 20101189 · DOI 10.1097/QAI.0b013e3181cbdaff

12-month study, 2 sequential phases (6-month double-blind 2:1 tesamorelin:placebo, then 6-month open extension). VAT decreased 10.9% (tesamorelin) vs 0.6% (placebo) at 6 months (P<0.0001); ~18% reduction with 12 months continuous use.

Supports: research_limitations, human_administration_status

Metabolic effects of a growth hormone-releasing factor in patients with HIV
New England Journal of Medicine, 2007 · Human Human · 412 HIV-positive patients (86% men) · Subcutaneous, daily · PMID 18057338 · DOI 10.1056/NEJMoa072375

Visceral adipose tissue decreased 15.2% (tesamorelin) vs increased 5.0% (placebo), P<0.001.

Supports: research_limitations, human_administration_status

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Journal of Infectious Diseases, 2025 · Human Human · 73 participants (HIV, abdominal obesity), multicenter (UC San Diego, UCSF, USC) · Subcutaneous · PMID 39813152 · DOI 10.1093/infdis/jiaf012

Open-label Phase 2, randomized 3:2 tesamorelin vs standard of care over 6 months. Trend toward improved neurocognitive performance (P=.060) but between-group difference not significant (P=.673) -- a genuine null result.

Supports: experimental_research

Ipamorelin
What is it?
A peptide that mimics the "hunger hormone" signal your body uses to trigger growth hormone release.
What are people researching/using it for?
Studied for stimulating natural growth hormone release.
Other uses being trialed
General GH-axis research, often studied alongside GHRH-type compounds
Worth knowing
Human studies in the literature include IV administration; this is descriptive of research routes only, not administration guidance.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Ghrelin/GH-secretagogue receptor agonism that stimulates GH release.
Pentapeptide · 5 amino acids · Synthetic
Primary Targets & Biological System
Ghrelin / GH-secretagogue signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A pentapeptide that activates the ghrelin receptor (GHSR1a) -- the same receptor the hunger hormone ghrelin normally binds -- which in the pituitary triggers growth hormone release. This is a mechanistically distinct route to GH release compared with GHRH-receptor agonists like tesamorelin or sermorelin; the two pathways can, in principle, be additive since they act through different receptors, which is part of why GHRH and GHRP/ghrelin-pathway compounds are often discussed together in GH-axis research. Ipamorelin is generally described in the literature as more selective for GH release, with comparatively less effect on other pituitary hormones than some earlier ghrelin-pathway secretagogues.
Research Areas
GH secretionPituitary physiologyEndocrine researchGhrelin receptor pharmacology
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
Approximately 2 hours
Human terminal half-life reported in human PK/PD research.
Research Routes
Subcutaneous (research contexts), Intravenous (human PK/PD research) (descriptive only — not administration or dosing guidance)
Key Differentiator
Acts through GHSR rather than the GHRH receptor.
Considerations
Research Limitations
Human studies in the literature include IV administration; this is descriptive of research routes only, not administration guidance.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Ipamorelin · A$74.95 A$89.95
Browse products →
View Research Sources (1) →
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Human Human · Healthy volunteers · Intravenous (PK/PD study) · PMID 10496658 · DOI 10.1023/A:1018955126402

Reports terminal half-life ~2h, clearance 0.078 L/h/kg, Vss 0.22 L/kg.

Supports: human_half_life

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.